Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Statistics

Total Valuation

NSE:JAGSNPHARM has a market cap or net worth of INR 10.95 billion. The enterprise value is 9.45 billion.

Market Cap	10.95B
Enterprise Value	9.45B

Important Dates

The last earnings date was Wednesday, January 21, 2026.

Earnings Date	Jan 21, 2026
Ex-Dividend Date	Sep 12, 2025

Share Statistics

NSE:JAGSNPHARM has 66.89 million shares outstanding. The number of shares has increased by 0.36% in one year.

Current Share Class	66.89M
Shares Outstanding	66.89M
Shares Change (YoY)	+0.36%
Shares Change (QoQ)	-1.30%
Owned by Insiders (%)	11.36%
Owned by Institutions (%)	1.45%
Float	16.31M

Valuation Ratios

The trailing PE ratio is 26.99.

PE Ratio	26.99
Forward PE	n/a
PS Ratio	3.89
PB Ratio	4.33
P/TBV Ratio	6.40
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	23.10
EV / Sales	3.36
EV / EBITDA	16.02
EV / EBIT	20.45
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	0.03
Debt / EBITDA	0.15
Debt / FCF	n/a
Interest Coverage	49.41

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	33.87%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	2.42%
Revenue Per Employee	2.01M
Profits Per Employee	292,373
Employee Count	1,399
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, NSE:JAGSNPHARM has paid 135.67 million in taxes.

Income Tax	135.67M
Effective Tax Rate	24.91%

Stock Price Statistics

The stock price has decreased by -28.27% in the last 52 weeks. The beta is -0.34, so NSE:JAGSNPHARM's price volatility has been lower than the market average.

Beta (5Y)	-0.34
52-Week Price Change	-28.27%
50-Day Moving Average	196.34
200-Day Moving Average	223.47
Relative Strength Index (RSI)	23.02
Average Volume (20 Days)	49,463

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, NSE:JAGSNPHARM had revenue of INR 2.82 billion and earned 409.03 million in profits. Earnings per share was 6.07.

Revenue	2.82B
Gross Profit	1.79B
Operating Income	461.99M
Pretax Income	544.70M
Net Income	409.03M
EBITDA	575.29M
EBIT	461.99M
Earnings Per Share (EPS)	6.07

Balance Sheet

The company has 1.59 billion in cash and 88.36 million in debt, with a net cash position of 1.50 billion or 22.49 per share.

Cash & Cash Equivalents	1.59B
Total Debt	88.36M
Net Cash	1.50B
Net Cash Per Share	22.49
Equity (Book Value)	2.53B
Book Value Per Share	37.80
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 63.47%, with operating and profit margins of 16.41% and 14.53%.

Gross Margin	63.47%
Operating Margin	16.41%
Pretax Margin	19.34%
Profit Margin	14.53%
EBITDA Margin	20.43%
EBIT Margin	16.41%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 2.50, which amounts to a dividend yield of 1.51%.

Dividend Per Share	2.50
Dividend Yield	1.51%
Dividend Growth (YoY)	25.00%
Years of Dividend Growth	1
Payout Ratio	n/a
Buyback Yield	-0.36%
Shareholder Yield	1.15%
Earnings Yield	3.73%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on January 8, 2025. It was a forward split with a ratio of 2.5.

Last Split Date	Jan 8, 2025
Split Type	Forward
Split Ratio	2.5

Scores

Altman Z-Score	n/a
Piotroski F-Score	2